吉首大学学报（自然科学版） ›› 2022, Vol. 43 ›› Issue (6): 67-74.DOI: 10.13438/j.cnki.jdzk.2022.06.012

• 医药 • 上一篇    下一篇

尼妥珠单抗联合GP治疗转移性鼻咽癌效果观察

陈佳，向志碧，熊莉，段和新，刘蓉，杨志，吴慧，杨再川   

  1. （湘西自治州人民医院肿瘤一科，湖南 吉首 416000）
  • 出版日期:2022-11-25 发布日期:2023-01-10
  • 通讯作者: 向志碧（1965—），女，湖南古丈人，主任医师，主要从事头颈部肿瘤的基础与放化疗研究.E-mail:2245755700@qq.com.
  • 作者简介:陈佳（1992—），女，湖南茶陵人，主治医师，硕士，主要从事头颈部肿瘤的基础与放化疗研究
  • 基金资助:
    吉首大学校级科研项目（JDLC1902）

Effect of Nimotuzumab Combined with GP Chemotherapy in the Treatment of Metastatic Nasopharyngeal Carcinoma

CHEN Jia,XIANG Zhibi,XIONG Li,DUAN Hexin,LIU Rong,YANG Zhi,WU Hui,YANG Zaichuan   

  1. (Department of Oncology,Xiangxi Autonomous Prefecture People's Hospital,the First Affiliated Hospital of Jishou University,Jishou 416000,Hunan China)
  • Online:2022-11-25 Published:2023-01-10

PDF (PC)

106

摘要：为了分析尼妥珠单抗联合吉西他滨+顺铂（GP）治疗晚期转移性鼻咽癌的疗效及不良反应，选取2019年6月至2020年12月在湘西州人民医院经病理及影像学确诊为转移性鼻咽癌的28例患者作为研究对象，随机分为GP+尼妥珠组（实验组，14例患者）和GP组（对照组，14例患者），对比分析两组患者的疾病客观有效率（ORR）、疾病控制率（DCR）、无进展生存期（PFS）、总生存期（OS）以及不良反应.结果表明：实验组CR，PR，SD，PD分别为1例、10例、2例、1例，对照组CR，PR，SD，PD分别为1例、6例、5例、2例，实验组、对照组的ORR分别为78.5%，50.0%（P=0.115），DCR分别为92.8%，85.7%（P=0.541），中位DOR分别为7个月、5个月（P=0.068），中位PFS分别为11个月、7个月（P=0.043），中位OS分别为19个月、13个月（P=0.043）；两组的主要不良反应均为骨髓抑制、消化道反应及肝功能损伤.实验组有11例患者出现了任意程度的骨髓抑制，对照组有12例患者出现了任意程度的骨髓抑制，两组差异无统计学意义（P=0.662）；实验组、对照组发生1~2级骨髓抑制率分别为50.00%，25.00%（P=0.115），发生3~4级骨髓抑制率分别为33.33%，64.28%（P=0.058）；实验组和对照组患者均仅出现了1~2级消化道反应，发生率分别为35.71%，50.00%（P=0.445），发生1级肝功能损伤率分别为21.43%，7.14%（P=0.280），2级肝功能损伤率分别为7.14%，7.14%（P=1）.与单纯的GP治疗方案相比，尼妥朱单抗联合GP治疗方案虽未提高转移性鼻咽癌患者的近期疗效，但延长了PFS时间，改善了总生存情况，且不增加不良反应.

关键词： 转移性鼻咽癌, 尼妥珠单抗, GP治疗, 疗效

Abstract: The efficacy and adverse reactions of nituzumab combined with GP chemotherapy in the treatment of metastatic nasopharyngeal carcinoma has been analyzed.Patients diagnosed by the pathology and the imaging of advanced metastatic nasopharyngeal carcinoma from June 1,2019 to December 31,2020 in Xiangxi Autonomous Prefecture People's Hospital,and were randomly divided into experimental group (GP + Nimotuzumab)and control group (GP) .The effective rate,disease control rate,progression-free survival,overall survival and adverse reactions of the two groups were compared and analyzed.A total of 28 patients were included in this study,including 14 in the experimental group and 14 in the control group.In the experimental group there were 1 case of CR,10 cases of PR,2 cases of SD,and 1 case of PD;and in the control group,ORR of the experimental group and control group was 78.5% vs 50.0%(P=0.115),and DCR 92.8% vs 85.7%(P=0.541).The median DOR was 7 months in the experimental group and 5 in the control group (P=0.068).The median PFS of the experimental group and the control group were 11 months and 7 months (P=0.043).The median OS was 19 months in experimental group and 13 months in control group (P=0.043) .The main adverse reactions in both groups were myelosuppression,gastrointestinal reactions and hepatic injury.Degrees of myelosuppression occurred in 11 patients in the experimental group and in 12 in the control group (P=0.662).The rates of grade 1~2 myelosuppression in the two groups were 50.00% vs 25.00% (P=0.115),while 3~4 grade in the two groups were (33.33% vs 64.28%,P=0.058).Grade 1~2 gastrointestinal reactions occurred in both groups 35.71% vs 50.00% (P=0.445).The incidence of grade 1~2 hepatic injury was (21.43% vs 7.14%,P=0.280),and that of grade 3~4 hepatic injury was the same (7.14%) .Compared with GP alone,GP +Nimotuzumab did not improve the short-term efficacy in the treatment of advanced metastatic nasopharyngeal carcinoma,but prolonged the PFS time,improved the overall survival,and did not increase the adverse reactions.

Key words: metastatic nasopharyngeal carcinoma, nimotuzumab, GP treatment, effect

版权所有 © 2021《吉首大学学报（自然科学版）》编辑部
技术支持：北京玛格泰克科技发展有限公司
公众号 电子书橱 超星期刊 手机浏览 在线QQ